[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"OMIQ Research\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100626533","comparison-of-visual-outcomes-and-patient-satisfaction-in-mild-to-moderate-glaucoma-patients-undergoing-cataract-surgery-with-edof-versus-monofocal-iols-100626533",false,"NCT07436871","Comparison of Visual Outcomes and Patient Satisfaction in Mild to Moderate Glaucoma Patients Undergoing Cataract Surgery With EDOF Versus Monofocal IOLs","A Randomized Clinical Trial for the Evaluation and Comparison of Visual Results and Patient Satisfaction in Patients With Primary Open-angle Glaucoma After Bilateral Implantation of an Extended Range of Vision Intraocular Lens Compared to a Monofocal Lens.","Inclusion criteria:\n\n* Patients of any sex aged 18 years or older willing to participate and sign the informed consent form.\n* Clinically significant cataracts in both eyes.\n* Patients clinically diagnosed of primary open angle glaucoma (POAG) in both eyes.\n* Early to moderate POAG, as defined by a mean deviation in the Humphrey Visual Field Analyzer (HFA) no worse than ≤ -12 dB and worse ≥ -2 dB at least in one eye, using a 24-2 SITA standard strategy\n* Two visual field tests without progression and stability of RNFL in Optical Coherence Tomography (OCT) thickness remaining same or less than 10 um in the previous 6 months, with pharmacologically controlled IOP in both eyes \\\u003C21mmHg.\n* Potential for post-surgery monocular distance corrected visual acuity of ≤ 0.10 LogMAR.\n* Normal corneal topography.\n* Able to attend all study visits.\n\nExclusion criteria:\n\n* Patients with uncontrolled glaucoma, defined as those with an IOP ≥21 mm Hg despite maximal medical therapy, requiring glaucoma surgery and\u002For laser in either eye in the next year.\n* Pre-surgery refractive error requiring IOL implantation beyond the commercially available range.\n* Patients with a not reliable visual field, a VFI ≤ 60% or defects of ≤ 10 dB in the 4 central points of the visual field.\n\nAny other form of glaucoma (pseudoexfoliative, severe forms of pigmentary, primary angle closure glaucoma, etc.), ocular hypertension, zonular instability or possible intuitive lens decentration after surgery.\n\n* Patients with any previous glaucoma surgery or any other ocular surgery that can affect the results, or any ocular surgery in the previous six months.\n* Any other ocular pathology that can affect the results.\n* Use of topic or systemic medication that may affect vision\n* Unable to cooperate to obtain consistent testing results.\n* Participation in any other trial during or within 30 days of the screening visit.","ALL","18 Years",{"count":19,"type":20},74,"ESTIMATED","INTERVENTIONAL",[23],"NA","Cataract is the leading cause of reversible vision loss, while glaucoma remains the primary cause of irreversible blindness, often impairing contrast sensitivity (CS), glare tolerance, and dark adaptation. These visual challenges are particularly relevant when selecting intraocular lenses (IOLs) for glaucoma patients undergoing cataract surgery.\n\nMonofocal IOLs are the safest and most commonly used option for glaucoma patients due to their optical simplicity and low incidence of photic phenomena, though they do not provide spectacle independence for near or intermediate vision. Multifocal IOLs (MFIOLs), while offering greater spectacle independence, are relatively contraindicated in glaucoma due to increased visual disturbances like glare and halos.\n\nExtended Depth of Focus (EDOF) IOLs offer an intermediate solution, using advanced optics to provide a continuous range of vision and fewer photic disturbances than MFIOLs. EDOF lenses have demonstrated good uncorrected distance and intermediate visual acuity in patients with mild to moderate glaucoma, with promising CS outcomes and high patient satisfaction. However, findings on CS performance remain inconsistent across studies.\n\nGiven these considerations, this study seeks to determine whether EDOF IOLs can be a viable alternative to monofocal lenses in glaucoma patients, potentially expanding their options for spectacle independence without compromising visual quality. The trial, conducted at OMIQ (Barcelona), will directly compare an EDOF IOL and a monofocal IOL made from the same material to assess their effects on visual acuity, contrast sensitivity, and photic phenomena in this specific patient population.",[26,27],"GLAUCOMA 1, OPEN ANGLE, D (Disorder)","Cataract",[29,30,31],"cataract surgery","Extended depth of focus intraocular lens","Primary open-angle glaucoma","NOT_YET_RECRUITING","2026-02-23",{"date":35,"type":36},"2026-02-27","ACTUAL",{"date":38,"type":20},"2026-01-31",{"date":40,"type":20},"2027-02",{"name":42,"class":43},"OMIQ Research","NETWORK",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100605644","visual-performance-of-clareon-vivity-and-puresee-iol-100605644","NCT07165197","Visual Performance of Clareon Vivity and PureSee IOL","Visual Performance of Clareon® Vivity® and PureSee® Intraocular Lenses in Patients Undergoing Cataract Surgery","PURVI2","Inclusion Criteria:\n\n* Patients of any sex and race aged 50 years or older\n* Patients undergoing bilateral age-related cataract surgery with a lens opacity grade 3 or higher in the LOCS III grading scale\n* Willing to receive implantation of an EDOF IOL\n* Willing to sign the informed consent and attend the study visits\n\nExclusion Criteria:\n\n* Requirement of a spherical or toric power of the IOL to achieve emmetropia beyond the available range of either of the two lenses\n* The number of patients included with low astigmatism that require an equivalent to a T2 toric IOL will be capped to 10 patients\u002Fgroup\n* Irregular astigmatism\n* Contact lens wear in the previous 3 weeks before biometry\n* Moderate or severe ocular surface, corneal, macular or optic nerve disease that in opinion of the investigator precludes the desired functional results\n* History of previous refractive, cornea, retina or glaucoma surgery\n* Eyes with a clear lens demanding a refractive lens exchange\n* Amblyopia in any eye\n* Significant previous ocular trauma\n* Pregnancy\n* A systemic condition that, in the opinion of the investigator, precludes the reliable assessments required in the study (i.e., dementia) or participation in the study (i.e., severe mobility problems).","50 Years",{"count":54,"type":20},80,[23],"This is study to determine the visual performance of patients with age-related cataracts implanted in both eyes with either of two extended depth of focus intraocular lenses, the Clareon Vivity (Alcon Healthcare) or the PureSee (Johnson \\& Johnson)",[27],"RECRUITING","2025-09-02",{"date":61,"type":36},"2025-09-10",{"date":63,"type":36},"2025-06-27",{"date":65,"type":20},"2026-03",{"name":42,"class":43},1,""]